Leerink Swann Starts Shire plc (SHPGY) at Market Perform; Growth Already Priced In; Wait for Better Entry
Tweet
Share
E-mailGet Alerts SHPGY Hot Sheet
Price: $85.67 -0.2%
Rating Summary:
8 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
8 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Leerink Swann initiates coverage on Shire plc (NASDAQ: SHPGY) with a Market Perform. PT $106.00.
Analyst, Jason M. Gerberry, said, "For existing investors, SHPGY offers (1) sales and EPS upside potential from geographic and label expansion of Vyvanse; (2) human genetic and regenerative medicines---long-tail assets with limited generic exposure; (3) an interesting early stage pipeline keyed to intrathecal delivery of enzyme replacement; and (4) a management team which has displayed solid execution. These factors are evenly balanced by (1) limited near-term catalysts to drive P/E expansion; (2) risk/reward heading into multiple patent trials; and (3) overhang from Sanofi-Aventis' (NYSE: SNY) (OP-rated) Eliglustat, a potential paradigm shifting Gaucher's treatment. Our discounted cash flow and probability weighted DCF analyses suggest a valuation of $106/ADS (~9% upside)."
For an analyst ratings summary and ratings history on Shire plc click here. For more ratings news on Shire plc click here.
Shares of Shire plc closed at $97.45 yesterday.
Analyst, Jason M. Gerberry, said, "For existing investors, SHPGY offers (1) sales and EPS upside potential from geographic and label expansion of Vyvanse; (2) human genetic and regenerative medicines---long-tail assets with limited generic exposure; (3) an interesting early stage pipeline keyed to intrathecal delivery of enzyme replacement; and (4) a management team which has displayed solid execution. These factors are evenly balanced by (1) limited near-term catalysts to drive P/E expansion; (2) risk/reward heading into multiple patent trials; and (3) overhang from Sanofi-Aventis' (NYSE: SNY) (OP-rated) Eliglustat, a potential paradigm shifting Gaucher's treatment. Our discounted cash flow and probability weighted DCF analyses suggest a valuation of $106/ADS (~9% upside)."
For an analyst ratings summary and ratings history on Shire plc click here. For more ratings news on Shire plc click here.
Shares of Shire plc closed at $97.45 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- Raymond James Starts Polaryx Therapeutics (PLYX) at Strong Buy
- BMO Capital Resumes Snowline Gold Corp (SGD:CN) (SNWGF) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
